Christopher Seiter Net Worth

Christopher Seiter biography

Christopher J. Seiter serves as Chief Financial Officer of the Company. Mr. Seiter has served as our Chief Financial Officer since May 2018. Prior to joining us, Mr. Seiter served as Chief Financial Officer of Millendo Therapeutics from October 2016 to April 2018. Previously, Mr. Seiter worked at Bank of America Merrill Lynch from 1999 until June 2016 and held various roles of increasing seniority, most recently serving as Managing Director, Head of Life Sciences Investment Banking. Prior to joining Bank of America Merrill Lynch, Mr. Seiter worked in the healthcare investment banking groups at UBS, Dillon Read and Kidder Peabody. Mr. Seiter also served in the U.S. Navy as a Nuclear Submarine Officer for five years. Mr. Seiter received a B.A. in economics cum laude from the University of Rochester and completed a graduate level program in nuclear engineering at the U.S. Naval Nuclear Power School.

How old is Christopher Seiter?

Christopher Seiter is 53, he's been the Chief Financial Officer of Trevi Therapeutics since 2018. There are 16 older and 3 younger executives at Trevi Therapeutics. The oldest executive at Trevi Therapeutics, Inc. is Anne VanLent, 72, who is the Independent Director.

What's Christopher Seiter's mailing address?

Christopher's mailing address filed with the SEC is C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, 14TH FLOOR, NEW HAVEN, CT, 06510.

Insiders trading at Trevi Therapeutics

Over the last 5 years, insiders at Trevi Therapeutics have traded over $2,844,492 worth of Trevi Therapeutics stock and bought 79,366,506 units worth $381,350,992 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Forest Baskett és Scott D Sandell. On average, Trevi Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $3,549,117. The most recent stock trade was executed by Jennifer L Good on 6 September 2024, trading 6,059 units of TRVI stock currently worth $8,664.

What does Trevi Therapeutics do?

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Trevi Therapeutics executives and stock owners

Trevi Therapeutics executives and other stock owners filed with the SEC include:

• Jennifer Good,
  President, Chief Executive Officer, Co-Founder, Director
• Thomas Sciascia,
  Co-Founder, Chief Medical Officer
• Jennifer L. Good,
  Co-Founder, CEO, Pres & Director
• Dr. Thomas R. Sciascia,
  Co-Founder & Chief Medical Officer
• Anne VanLent,
  Independent Director
• Edward Mathers,
  Director
• Michael Heffernan,
  Independent Director
• Dominick Colangelo,
  Director
• James Cassella,
  Independent Director
• Helena Brett-Smith,
  Chief Development Officer
• Christopher Seiter,
  Chief Financial Officer
• David Meeker,
  Independent Chairman of the Board
• Danine Summers,
  VP of Medical Affairs
• Dr. William P. Forbes Pharm. D., Pharm.D.,
  Chief Devel. Officer
• Christopher Galletta,
  Controller & Chief Accounting Officer
• Lisa Delfini,
  Chief Financial Officer
• Frank P. Muscolo,
  Exec. Officer
• Dr. William P. Forbes Pharm.D., Pharm. D.,
  Chief Devel. Officer
• Dr. Amale Hawi,
  Sr. VP of CMC
• Christopher J. Seiter,
  Chief Financial Officer
• Christopher Galletta,
  See Remarks
• Farrell Simon,
  Chief Commercial Officer
• Peter W. Sonsini,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Frank P Muscolo,
  Controller
• Group Holdings (Sbs) Adviso...,
  
• Ali Behbahani,
  10% owner
• Scott D Sandell,
  10% owner
• Yann Mazabraud,
  See Remarks
• Enterprise Associates 16, L...,
  
• Carmen Chang,
  10% owner
• Debra A Drake,
  10% owner
• William J Oshea,
  10% owner
• Fund V, L.P.Omega Fund V Gp...,
  
• David M Mott,
  10% owner
• Venture Partners Iv, L.P.Ap...,
  
• Eran Nadav,
  Director
• Invest A/S Lundbeckfond,
  10% owner
• Family Investment Co Vmfic ...,
  
• Joshua Makower,
  10% owner
• Mette Kirstine Agger,
  Director
• Peter J Barris,
  10% owner
• Anna Guyer Mitsak,
  Director
• Forest Baskett,
  10% owner
• King Mellon Foundation Richard,
  10% owner
• Paul Edward Walker,
  10% owner
• William P Forbes,
  Chief Development Officer
• Gp A, Llcbonderman Davidcou...,
  
• David J Clark,
  Chief Medical Officer
• Lisa Delfini,
  Chief Financial Officer